Photo by Jason Briscoe on Unsplash
 

As part of our ongoing series at The Acquirer’s Multiple, each week we spotlight a stock from our Stock Screeners that may represent a deeply undervalued opportunity hiding in plain sight. This week’s spotlight is SIGA Technologies Inc. — a niche biodefense pharmaceutical company with a highly profitable antiviral franchise, fortress balance sheet, and extraordinary valuation metrics that suggest the market is dramatically underestimating its intrinsic worth.
 

Business Overview

SIGA Technologies is a specialty pharmaceutical company focused on the treatment and prevention of orthopoxvirus infections. Its flagship product, TPOXX (tecovirimat), is approved for the treatment of smallpox and is primarily sold to government agencies under long-term procurement and preparedness programs.

Unlike traditional biotech firms, SIGA is not a cash-burning R&D story. It operates a lean model with minimal overhead, high margins, and revenue driven by contracted government demand rather than consumer uptake. This structure allows SIGA to convert a large portion of revenue directly into operating income and free cash flow.
 

What Is IV/P (Intrinsic Value to Price)?

IV/P compares a company’s estimated intrinsic value to its current market price by incorporating earnings power, reinvestment needs, and capital efficiency.

IV/P > 1 → Undervalued
IV/P < 1 → Overvalued

SIGA’s IV/P = 3.90, meaning intrinsic value is estimated to be nearly four times the current share price — an exceptionally strong signal of undervaluation and one of the highest IV/P readings across our entire coverage universe.
 

Supporting Metrics

Market Cap: ≈ US$ 400–450M
Enterprise Value: ≈ US$ 230–260M
Free Cash Flow (TTM): ≈ US$ 116M
FCF Yield: ≈ 45–50% on EV
Acquirer’s Multiple: AM = 3.01

An Acquirer’s Multiple of 3.01 places SIGA in extreme deep-value territory. At this level, the market is effectively valuing the company as though its earnings are temporary or at risk of disappearing, despite strong profitability and ongoing cash accumulation.
 

Revenue & Profitability

Revenue (TTM): ≈ US$ 172M
Operating Income: ≈ US$ 90M
Operating Margin: ≈ 52%
Net Income: ≈ US$ 74M
Net Margin: ≈ 43%
Diluted EPS: ≈ 1.03

SIGA’s margins are exceptional, rivaling or exceeding those of elite software companies. The firm converts more than half of its revenue into operating income — a rare outcome in pharmaceuticals — reflecting its focused product portfolio and minimal operating complexity.
 

Balance Sheet Strength

Cash & Equivalents: ≈ US$ 172M
Total Debt: ≈ US$ 0.6M
Net Cash: ≈ US$ 171M
Shareholders’ Equity: ≈ US$ 203M
Working Capital: ≈ US$ 203M

SIGA operates with virtually no debt and a massive net cash position relative to its market capitalization. The balance sheet alone covers a substantial portion of the company’s valuation, sharply limiting downside risk while preserving maximum strategic flexibility.
 

Capital Returns

Dividends Paid (TTM): ≈ US$ 43M
Free Cash Flow (TTM): ≈ US$ 116M

SIGA has returned significant capital to shareholders via dividends while continuing to grow its cash balance. With an IV/P of 3.90, each dollar returned or retained compounds intrinsic value at an unusually high rate.
 

Why SIGA Might Be Undervalued

The market appears to discount SIGA due to its perceived dependence on a single product and lumpy government procurement cycles. Biodefense stocks also tend to be overlooked outside of crisis periods, leading to persistent valuation gaps.

Despite these concerns, SIGA continues to generate over US$ 100M in annual free cash flow, carries negligible debt, and maintains monopoly-like economics in a mission-critical niche. An IV/P of 3.90 and an Acquirer’s Multiple of 3.01 suggest the market is pricing the company as if its earnings are fleeting — a view that appears inconsistent with its financial reality.
 

Conclusion

With an IV/P of 3.90, an exceptionally low Acquirer’s Multiple of 3.01, and more than US$ 100M in annual free cash flow, SIGA Technologies Inc. stands out as a rare deep-value opportunity with minimal balance sheet risk and extraordinary profitability.

Its dominant position in a critical biodefense market, massive net cash balance, and shareholder-friendly capital returns point to a business that is materially mispriced. For value investors seeking high-margin cash generation at a steep discount to intrinsic value, SIGA represents a compelling and asymmetric opportunity.

More By This Author:

Domino’s Pizza Inc: Our Calculation Of Intrinsic Value
Book Review: Supermoney: How Institutions, Incentives, And Illusions Took Over The Market
This Week’s Deep-Value Stocks: Financials And Cyclicals Dominate The Screen